Study: Ivermectin Led to a 92% Reduction in COVID-19 Mortality Rate
A recent peer reviewed study by authors, Kerr L, Baldi F, Lobo R, et al. (August 31, 2022), demonstrated that ivermectin used as prophylaxis effectively reduced infection, hospitalization, and mortality rates for CV-19 by 92%.
The Emergency Use Authorization for the experimental warp speed jab could not have lawfully been approved if preventative treatments such as Ivermectin and HCQ were readily available. These cures were suppressed and those who questioned the official narrative were ridiculed and punished. A pandemic, lockdowns, closed businesses, masks, distancing — none of the covid theatre was necessary. Millions could have been spared injury, suffering and death by the unsafe CV-19 jab.
The injections must be halted immediately and those responsible prosecuted. -JD
Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
Authors:
Conclusion
Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.
Introduction
Ivermectin has been proposed as potential prophylaxis and therapy for coronavirus disease 2019 (COVID-19) due to its previously reported anti-viral [1-4], metabolic [5-10], and anti-inflammatory [11-19] actions, with strong plausibility [20,21] and positive in vitro, in vivo, and epidemiological findings [22-24] in preliminary studies.
Between July and December 2020, a citywide program in Itajaí, in the state of Santa Catarina, Southern Brazil, offered a voluntary, medically prescribed program of ivermectin as prophylaxis for COVID-19. This was based on the extensive, well-established safety profile and known absence of risks with long-term use of ivermectin, and the lack of therapeutic and preventive alternative options in 2020.
The systematically collected data within this program demonstrated that ivermectin used as prophylaxis for COVID-19 improved COVID-19 related-outcomes. The use of ivermectin led to a 44% reduction in infection rate, a 56% reduction in hospitalization rate, and a 68% reduction in mortality rate by using propensity score matching (PSM) to balance the study groups [25].
These conclusions were based on an analog evaluation of the intent-to-treat (ITT) analysis of randomized clinical trials (RCTs). All participants of the program were included for analysis, irrespective of regularity or the total amount of ivermectin taken. Among participants of the ivermectin use (regular and irregular) as prophylaxis for the COVID-19 program, it was unknown if regular ivermectin use would lead to a more substantial reduction in COVID-19 infection rate and related outcomes than irregular use.
In this study, an evaluation was done with participants that used ivermectin prophylactically for COVID-19, to determine if regular use compared to irregular use impacted the degree of reduction in COVID-19 infection, hospitalization, and mortality rates. Regular and irregular ivermectin users were also compared to non-users to evaluate evidence of a dose-response pattern of efficacy.
Link To Article HERE